Evaluating the Role and Policy Implications of Using External Evidence in Survival Extrapolations: A Case Study of Axicabtagene Ciloleucel Therapy for Second-Line DLBCL.

Detalles Bibliográficos
Publicado en:PharmacoEconomics Vol. 43; no. 11; pp. 1293 - 1308
Autores principales: Harper, Sam, Afonso, Daniela, Watts, Karina, Doble, Brett, Eklund, Oskar, Vadgama, Sachin, Snider, Julia Thornton, Palmer, Stephen, Taylor, Matthew
Formato: Journal Article
Publicado: Springer Nature Nov2025
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=188778332&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 188778332
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        11707690
        C5G
      jtl: PharmacoEconomics
      issn: 11707690
      maglogo: N
    pubinfo:
      dt: Nov2025
      vid: 43
      iid: 11
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        188778332
        187181937
        10.1007/s40273-025-01529-5
        188778332
      ppf: 1293
      ppct: 15
      formats:
      tig:
        atl: Evaluating the Role and Policy Implications of Using External Evidence in Survival Extrapolations: A Case Study of Axicabtagene Ciloleucel Therapy for Second-Line DLBCL.
      aug:
        au:
          Harper, Sam
          Afonso, Daniela
          Watts, Karina
          Doble, Brett
          Eklund, Oskar
          Vadgama, Sachin
          Snider, Julia Thornton
          Palmer, Stephen
          Taylor, Matthew
        affil: https://ror.org/04m01e293 York Health Economics Consortium, University of York, Heslington, York, UK
      sug:
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
      ab:
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N